Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan
Crossref DOI link: https://doi.org/10.1007/s00198-017-3973-8
Published Online: 2017-03-06
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Moriwaki, K.
Mouri, M.
Hagino, H.
Funding for this research was provided by:
Asahi Kasei Pharma Corporation
License valid from 2017-03-06